{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:14:05Z","timestamp":1793924045216,"version":"4.8.0"},"reference-count":234,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Inflammation plays a pivotal role in the pathogenesis of acute coronary syndromes (ACS), contributing to plaque instability, thrombosis, and myocardial injury. This review aims to comprehensively examine the inflammatory mechanisms underlying ACS and evaluate current and emerging anti-inflammatory therapeutic strategies. We conducted a comprehensive literature review examining the role of inflammatory pathways in ACS pathophysiology, including innate and adaptive immune responses, key inflammatory mediators, and cellular mechanisms. We analyzed current evidence for anti-inflammatory therapies and their clinical outcomes in ACS management. Inflammatory processes in ACS involve complex interactions between innate immune cells (neutrophils, macrophages, monocytes) and adaptive immune cells (T lymphocytes, B cells). Key mechanisms include neutrophil extracellular trap (NET) formation, macrophage polarization, T cell subset imbalances (Th1\/Th17 predominance with regulatory T cell dysfunction), and complement activation. Inflammatory biomarkers such as C-reactive protein, interleukin-6, and NET-specific markers demonstrate prognostic value. Anti-inflammatory therapies including colchicine, canakinumab (IL-1\u03b2 inhibition), and methotrexate have shown cardiovascular benefits in clinical trials. Emerging targets include NET inhibition, T cell modulation, and precision inflammatory profiling approaches. Inflammation represents a critical therapeutic target in ACS beyond traditional risk factor modification. While colchicine and IL-1\u03b2 inhibition have demonstrated clinical efficacy, future strategies should focus on precision medicine approaches targeting specific inflammatory pathways based on individual patient profiles. Integration of anti-inflammatory therapy with lipid management and antithrombotic strategies offers promise for improving ACS outcomes through comprehensive targeting of the multifactorial pathophysiology underlying coronary artery disease.<\/jats:p>","DOI":"10.3390\/cells15010072","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T17:24:58Z","timestamp":1767201898000},"page":"72","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Inflammatory Mechanisms in Acute Coronary Syndromes: From Pathophysiology to Therapeutic Targets"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-456X","authenticated-orcid":false,"given":"Daniel Miron","family":"Brie","sequence":"first","affiliation":[{"name":"Cardiovascular Disease Institute Timisoara, Gheorghe Adam Street, No. 13A, 300310 Timisoara, Romania"},{"name":"Research Center of the Institute of Cardiovascular Diseases, Gheorghe Adam Street, No. 13A, 300310 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6096-9601","authenticated-orcid":false,"given":"Cristian","family":"Morno\u0219","sequence":"additional","affiliation":[{"name":"Cardiovascular Disease Institute Timisoara, Gheorghe Adam Street, No. 13A, 300310 Timisoara, Romania"},{"name":"Research Center of the Institute of Cardiovascular Diseases, Gheorghe Adam Street, No. 13A, 300310 Timisoara, Romania"},{"name":"Department of Cardiology, \u201cVictor Babes\u201d University of Medicine and Pharmacy, Eftimie Murgu Square, No. 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidiu","family":"Adam","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery and Orthopedics, \u201cVictor Babes\u201d University of Medicine and Pharmacy, Eftimie Murgu Square, No. 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru","family":"T\u00eerziu","sequence":"additional","affiliation":[{"name":"Cardiovascular Disease Institute Timisoara, Gheorghe Adam Street, No. 13A, 300310 Timisoara, Romania"},{"name":"Department of Functional Sciences, \u201cVictor Babes\u201d University of Medicine and Pharmacy, Tudor Vladimirescu Street, No. 14, 300174 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9387-1141","authenticated-orcid":false,"given":"Roxana","family":"Popescu","sequence":"additional","affiliation":[{"name":"ANAPATMOL Research Center, \u201cVictor Babes\u201d University of Medicine and Pharmacy, Tudor Vladimirescu Street, No. 14, 300174 Timisoara, Romania"},{"name":"Department of Cell and Molecular Biology, Faculty of Medicine, \u201cVictor Babes\u201d University of Medicine and Pharmacy, Eftimie Murgu Square, No. 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina Didu\u021ba","family":"Brie","sequence":"additional","affiliation":[{"name":"Department of Cell and Molecular Biology, Faculty of Medicine, \u201cVictor Babes\u201d University of Medicine and Pharmacy, Eftimie Murgu Square, No. 2, 300041 Timisoara, Romania"},{"name":"\u201cLouis \u021aurcanu\u201d Emergency Children Hospital, Doctor Iosif Nemoianu Street, No. 2, 300011 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/eurheartj\/ehad486","article-title":"Inflammation in acute myocardial infarction: The good, the bad and the ugly","volume":"45","author":"Matter","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.2967\/jnumed.107.038661","article-title":"Role of Inflammation in Atherosclerosis","volume":"48","author":"Spagnoli","year":"2007","journal-title":"J. Nucl. Med."},{"key":"ref_5","first-page":"577","article-title":"Vulnerable atherosclerotic plaque features: Findings from coronary imaging","volume":"18","author":"Kurihara","year":"2021","journal-title":"J. Geriatr. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/0735-1097(94)90772-2","article-title":"Triggers, acute risk factors and vulnerable plaques: The lexicon of a new frontier","volume":"23","author":"Muller","year":"1994","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1161\/01.ATV.20.5.1262","article-title":"Lessons From Sudden Coronary Death: A Comprehensive Morphological Classification Scheme for Atherosclerotic Lesions","volume":"20","author":"Virmani","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1161\/01.CIR.0000087480.94275.97","article-title":"From Vulnerable Plaque to Vulnerable Patient","volume":"108","author":"Naghavi","year":"2003","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.CIR.92.5.1355","article-title":"A Definition of Advanced Types of Atherosclerotic Lesions and a Histological Classification of Atherosclerosis","volume":"92","author":"Stary","year":"1995","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Caldarelli, M., Franza, L., Cutrupi, S., Menegolo, M., Franceschi, F., Gasbarrini, A., Gambassi, G., and Cianci, R. (2025). Inflammasomes in Cardiovascular Diseases: Current Knowledge and Future Perspectives. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26125439"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.redox.2015.01.008","article-title":"NLRP3 inflammasome: From a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases","volume":"4","author":"Abderrazak","year":"2015","journal-title":"Redox Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41598-024-85041-4","article-title":"The effect of NLRP3 inflammasome on cardiovascular prognosis in patients with acute coronary syndrome","volume":"15","author":"Mo","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1561342","DOI":"10.1155\/2020\/1561342","article-title":"NLRP3 Inflammasome: A Potential Alternative Therapy Target for Atherosclerosis","volume":"2020","author":"Liu","year":"2020","journal-title":"Evid.-Based Complement. Altern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"108053","DOI":"10.1016\/j.pharmthera.2021.108053","article-title":"Targeting the NLRP3 inflammasome in car-diovascular diseases","volume":"236","author":"Toldo","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Chai, R., Xue, W., Shi, S., Zhou, Y., Du, Y., Li, Y., Song, Q., Wu, H., and Hu, Y. (2022). Cardiac Remodeling in Heart Failure: Role of Pyroptosis and Its Therapeutic Implications. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.870924"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Seok, J.K., Kang, H.C., Cho, Y.-Y., Lee, H.S., and Lee, J.Y. (2021). Regulation of the NLRP3 Inflammasome by Post-Translational Modifications and Small Molecules. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.618231"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Mo, B., Ding, Y., and Ji, Q. (2025). NLRP3 inflammasome in cardiovascular diseases: An update. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1550226"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5525917","DOI":"10.1155\/2021\/5525917","article-title":"The Inflammasome Signaling Pathway Is Actively Regulated and Related to Myocardial Damage in Coronary Thrombi from Patients with STEMI","volume":"2021","author":"Nordeng","year":"2021","journal-title":"Mediat. Inflamm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jacbts.2019.02.007","article-title":"Inflammasome-Driven Interleukin-1\u03b1 and Interleukin-1\u03b2 Production in Atherosclerotic Plaques Relates to Hyperlipidemia and Plaque Complexity","volume":"4","author":"Jiang","year":"2019","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1161\/01.CIR.0000125700.33637.B1","article-title":"Increased Expression of Interleukin-1 in Coronary Artery Disease with Downregulatory Effects of HMG-CoA Reductase Inhibitors","volume":"109","author":"Yndestad","year":"2004","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ceca.2010.02.002","article-title":"TNF-\u03b1 and IL-1\u03b2 increase Ca2+ leak from the sarcoplasmic reticulum and susceptibility to arrhythmia in rat ventricular myocytes","volume":"47","author":"Duncan","year":"2010","journal-title":"Cell Calcium"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00005-009-0024-y","article-title":"The role of IL-1 in the pathogenesis of heart disease","volume":"57","author":"Bujak","year":"2009","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/clc.4960241103","article-title":"Interleukin-6 and acute coronary syndrome","volume":"24","author":"Ikeda","year":"2001","journal-title":"Clin. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Tsioufis, P., Theofilis, P., Tsioufis, K., and Tousoulis, D. (2022). The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415937"},{"key":"ref_25","first-page":"185","article-title":"Interleukin-6 and High-sensitivity C-reactive Protein for the Prediction of Outcomes in Non-ST-segment Elevation Acute Coronary Syndromes","volume":"66","author":"Lip","year":"2013","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Nakao, T., and Libby, P. (2023). IL-6 Helps Weave the Inflammatory Web during Acute Coronary Syndromes. J. Clin. Investig., 133.","DOI":"10.1172\/JCI167670"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e2690","DOI":"10.6061\/clinics\/2021\/e2690","article-title":"Meta-analysis of the relationship between interleukin-6 levels and the prognosis and severity of acute coronary syndrome","volume":"76","author":"Yang","year":"2021","journal-title":"Clinics"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11883-024-01259-7","article-title":"IL-6 and Cardiovascular Risk: A Narrative Review","volume":"27","author":"Mehta","year":"2025","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e005637","DOI":"10.1161\/JAHA.117.005637","article-title":"Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib\u2014Thrombolysis in Myocardial Infarction 52) Trial","volume":"6","author":"Fanola","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.34172\/jcvtr.2023.31844","article-title":"Evaluation of MMP-9, IL-6, TNF-\u03b1 levels and peripheral blood mononuclear cells genes expression of MMP-9 and TIMP-1 in Iranian patients with coronary artery disease","volume":"15","author":"Akbari","year":"2023","journal-title":"J. Cardiovasc. Thorac. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.2174\/1381612826666200413082353","article-title":"Pro-inflammatory Cytokines in Acute Coronary Syndromes","volume":"26","author":"Mourouzis","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s00296-022-05113-4","article-title":"Assessment of TNF-\u03b1 expression in unstable atherosclerotic plaques, serum IL-6 and TNF-\u03b1 levels in patients with acute coronary syndrome and rheumatoid arthritis","volume":"42","author":"Popova","year":"2022","journal-title":"Rheumatol. Int."},{"key":"ref_33","first-page":"18","article-title":"Tumor necrosis factor-\u03b1 and its role as a mediator in myocardial infarction: A brief review","volume":"1","author":"Tian","year":"2015","journal-title":"Chronic Dis. Transl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1172\/JCI29134","article-title":"TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways","volume":"117","author":"Haudek","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1161\/ATVBAHA.111.224915","article-title":"Mechanisms of Cell Death in Heart Disease","volume":"32","author":"Konstantinidis","year":"2012","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3439768","DOI":"10.1155\/2022\/3439768","article-title":"Clinical Features of Acute Coronary Syndrome in Patients with Coronary Heart Disease and Its Correlation with Tumour Necrosis Factor in Cardiology","volume":"2022","author":"Guo","year":"2022","journal-title":"Comput. Math. Methods Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1157\/13113928","article-title":"Valor pron\u00f3stico del factor de necrosis tumoral alfa en pacientes con infarto agudo de miocardio con elevaci\u00f3n del segmento ST","volume":"60","author":"Lozano","year":"2007","journal-title":"Rev. Espa\u00f1ola Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Shi, N., Wei, L., Wang, H., Sun, S., Yang, J., and Zhou, Y. (2025). Regulation of pyroptosis by natural products in atherosclerosis: Mechanisms and therapeutic potential. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1626566"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e24229","DOI":"10.1002\/clc.24229","article-title":"Prognostic significance of IL-18 in acute coronary syndrome patients","volume":"47","author":"Xiong","year":"2024","journal-title":"Clin. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/imr.12616","article-title":"Interleukin-18: Biological properties and role in disease pathogenesis","volume":"281","author":"Kaplanski","year":"2018","journal-title":"Immunol. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1161\/01.ATV.0000153516.02782.65","article-title":"IL-18 Accelerates Atherosclerosis Accompanied by Elevation of IFN-\u03b3 and CXCL16 Expression Independently of T Cells","volume":"25","author":"Tenger","year":"2005","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/clc.23274","article-title":"Interleukin-18 in patients with acute coronary syndromes","volume":"42","author":"James","year":"2019","journal-title":"Clin. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1161\/ATVBAHA.109.202697","article-title":"Interleukin-18 as a Predictor of Future Events in Patients with Acute Coronary Syndromes","volume":"30","author":"Hartford","year":"2010","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1161\/ATVBAHA.107.161240","article-title":"Chemokines and Cardiovascular Risk","volume":"28","author":"Aukrust","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0735-1097(00)01110-4","article-title":"Interaction between chemokines and oxidative stress: Possible pathogenic role in acute coronary syndromes","volume":"37","author":"Aukrust","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11883-025-01294-y","article-title":"The Atherosclerotic Plaque Microenvironment as a Therapeutic Target","volume":"27","author":"Pandit","year":"2025","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jacc.2019.06.030","article-title":"Homeostatic Chemokines and Prognosis in Patients with Acute Coronary Syndromes","volume":"74","author":"Caidahl","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Zhang, H., Yang, K., Chen, F., Liu, Q., Ni, J., Cao, W., Hua, Y., He, F., Liu, Z., and Li, L. (2022). Role of the CCL2-CCR2 axis in cardiovascular disease: Pathogenesis and clinical implications. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.975367"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"154923","DOI":"10.1016\/j.cyto.2019.154923","article-title":"Chemokine (C-C motif) ligand 2 and coronary artery disease: Tissue expression of functional and atypical receptors","volume":"126","author":"Fibla","year":"2020","journal-title":"Cytokine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41421-022-00403-4","article-title":"Molecular insights into ligand recognition and activation of chemokine receptors CCR2 and CCR3","volume":"8","author":"Shao","year":"2022","journal-title":"Cell Discov."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Stangret, A., Sadowski, K.A., Jab\u0142o\u0144ski, K., Kochman, J., Opolski, G., Grabowski, M., and Tomaniak, M. (2024). Chemokine Fractalkine and Non-Obstructive Coronary Artery Disease\u2014Is There a Link?. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25073885"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"De Jager, S.C.A., Bongaerts, B.W.C., Weber, M., Kraaijeveld, A.O., Rousch, M., Dimmeler, S., Van Dieijen-Visser, M.P., Cleutjens, K.B.J.M., Nelemans, P.J., and Van Berkel, T.J.C. (2012). Chemokines CCL3\/MIP1\u03b1, CCL5\/RANTES and CCL18\/PARC are Independent Risk Predictors of Short-Term Mortality in Patients with Acute Coronary Syndromes. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0045804"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.yjmcc.2008.06.003","article-title":"CCL3 (MIP-1\u03b1) levels are elevated during acute coronary syndromes and show strong prognostic power for future ischemic events","volume":"45","author":"Kraaijeveld","year":"2008","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_54","first-page":"e75","article-title":"Leukocyte-Specific CCL3 Deficiency Inhibits Atherosclerotic Lesion Development by Affecting Neutrophil Accumulation","volume":"33","author":"Bot","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1161\/HYPERTENSIONAHA.120.14698","article-title":"Chemokine Receptor CXCR-2 Initiates Atrial Fibrillation by Triggering Monocyte Mobilization in Mice","volume":"76","author":"Zhang","year":"2020","journal-title":"Hypertension"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"8396484","DOI":"10.1155\/2020\/8396484","article-title":"Molecular Targets and Pathways Contributing to the Effects of Wenxin Keli on Atrial Fibrillation Based on a Network Pharmacology Approach","volume":"2020","author":"Zhang","year":"2020","journal-title":"Evid.-Based Complement. Altern. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41420-023-01524-9","article-title":"The role of CXCL family members in different diseases","volume":"9","author":"Zhou","year":"2023","journal-title":"Cell Death Discov."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Deng, J., Jiang, R., Meng, E., and Wu, H. (2022). CXCL5: A coachman to drive cancer progression. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.944494"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.gendis.2021.08.004","article-title":"CCL5\/CCR5 axis in human diseases and related treatments","volume":"9","author":"Zeng","year":"2022","journal-title":"Genes Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"100220","DOI":"10.1016\/j.ahjo.2022.100220","article-title":"CXCL5 gene polymorphisms and coronary collateralization","volume":"23","author":"Keeley","year":"2022","journal-title":"Am. Heart J. Plus Cardiol. Res. Pract."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/j.ajpath.2017.08.006","article-title":"Clinical Evidence Supports a Protective Role for CXCL5 in Coronary Artery Disease","volume":"187","author":"Ravi","year":"2017","journal-title":"Am. J. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1161\/CIRCRESAHA.118.314028","article-title":"Tissue Resident CCR2\u2212 and CCR2+ Cardiac Macrophages Differentially Orchestrate Monocyte Recruitment and Fate Specification Following Myocardial Injury","volume":"124","author":"Bajpai","year":"2019","journal-title":"Circ. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1084\/jem.20070885","article-title":"The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions","volume":"204","author":"Nahrendorf","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1161\/ATVBAHA.108.180513","article-title":"Monocytes in Acute Coronary Syndromes","volume":"29","author":"Shantsila","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.jacc.2013.07.043","article-title":"Monocytes in Coronary Artery Disease and Atherosclerosis","volume":"62","author":"Ghattas","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/cvr\/cvz336","article-title":"Cardiac monocytes and macrophages after myocardial infarction","volume":"116","author":"Peet","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.21037\/jtd.2016.11.17","article-title":"Monocytes and macrophages in cardiac injury and repair","volume":"9","author":"Sager","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1161\/CIRCRESAHA.116.309001","article-title":"Proliferation and Recruitment Contribute to Myocardial Macrophage Expansion in Chronic Heart Failure","volume":"119","author":"Sager","year":"2016","journal-title":"Circ. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/01.CIR.0000042674.89762.20","article-title":"Neutrophil Infiltration of Culprit Lesions in Acute Coronary Syndromes","volume":"106","author":"Naruko","year":"2002","journal-title":"Circulation"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nri.2017.105","article-title":"Neutrophil extracellular traps in immunity and disease","volume":"18","author":"Papayannopoulos","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1161\/CIRCRESAHA.116.304944","article-title":"Coronary Neutrophil Extracellular Trap Burden and Deoxyribonuclease Activity in ST-Elevation Acute Coronary Syndrome Are Predictors of ST-Segment Resolution and Infarct Size","volume":"116","author":"Mangold","year":"2015","journal-title":"Circ. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12950-023-00344-z","article-title":"Neutrophil Extracellular Traps in Acute Coronary Syndrome. 2023","volume":"20","author":"Wu","year":"2023","journal-title":"J. Inflamm."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJM197406062902302","article-title":"The Leukocyte Count as a Predictor of Myocardial Infarction","volume":"290","author":"Friedman","year":"1974","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/ATVBAHA.113.301627","article-title":"Elevated Levels of Circulating DNA and Chromatin Are Independently Associated with Severe Coronary Atherosclerosis and a Prothrombotic State","volume":"33","author":"Borissoff","year":"2013","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3892\/br.2025.1991","article-title":"NETosis in myocardial ischemia-reperfusion injury: From mechanisms to therapies (Review)","volume":"23","author":"Zhang","year":"2025","journal-title":"Biomed. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Szyma\u0144ska, Z., Staniewski, A., Karpi\u0144ski, M., Zalewska, K., Kalus, O., Gramala, Z., Ma\u0107kowiak, J., Mertowski, S., Filipiak, K.J., and Rahnama-Hezavah, M. (2025). The Role of Neutrophil Extracellular Networks in Cardiovascular Pathology. Cells, 14.","DOI":"10.3390\/cells14191562"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1160\/TH11-09-0650","article-title":"Presence of luminal neutrophil extracellular traps in atherosclerosis","volume":"107","author":"Megens","year":"2012","journal-title":"Thromb. Haemost."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1177\/1535370220945989","article-title":"The implications of neutrophil extracellular traps in the pathophysiology of atherosclerosis and atherothrombosis","volume":"245","author":"Mostafa","year":"2020","journal-title":"Exp. Biol. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"165542","DOI":"10.1016\/j.bbadis.2019.165542","article-title":"Glycolysis dependent lactate formation in neutrophils: A metabolic link between NOX-dependent and independent NETosis","volume":"1865","author":"Awasthi","year":"2019","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Basis Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"103231","DOI":"10.1016\/j.redox.2024.103231","article-title":"Cathepsin C from extracellular histone-induced M1 alveolar macrophages promotes NETosis during lung ischemia-reperfusion injury","volume":"74","author":"Yu","year":"2024","journal-title":"Redox Biol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Sun, L., Wu, Q., Nie, Y., Cheng, N., Wang, R., Wang, G., Zhang, D., He, H., Ye, R.D., and Qian, F. (2018). A Role for MK2 in Enhancing Neutrophil-Derived ROS Production and Aggravating Liver Ischemia\/Reperfusion Injury. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02610"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1656450","DOI":"10.1155\/2016\/1656450","article-title":"The Role of Oxidative Stress in Myocardial Ischemia and Reperfusion Injury and Remodeling: Revisited","volume":"2016","author":"AKurian","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1160\/TH11-02-0096","article-title":"Neutrophils and clinical outcomes in patients with acute coronary syndromes and\/or cardiac revascularisation","volume":"106","author":"Guasti","year":"2011","journal-title":"Thromb. Haemost."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/ATVBAHA.123.320409","article-title":"Single-Cell RNA Sequencing Reveals an Immune Landscape of CD4+ T Cells in Coronary Culprit Plaques with Acute Coronary Syndrome in Humans\u2014Brief Report","volume":"44","author":"Takeda","year":"2024","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/j.jacc.2016.08.036","article-title":"Adaptive Immunity Dysregulation in Acute Coronary Syndromes","volume":"68","author":"Flego","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1161\/CIRCRESAHA.109.206052","article-title":"Insufficient Deactivation of the Protein Tyrosine Kinase Lck Amplifies T-Cell Responsiveness in Acute Coronary Syndrome","volume":"106","author":"Pryshchep","year":"2010","journal-title":"Circ. Res."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Chen, J., Xiang, X., Nie, L., Guo, X., Zhang, F., Wen, C., Xia, Y., and Mao, L. (2023). The emerging role of Th1 cells in atherosclerosis and its implications for therapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1079668"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00392-012-0465-x","article-title":"TNF-\u03b1, myocardial perfusion and function in patients with ST-segment elevation myocardial infarction and primary percutaneous coronary intervention","volume":"101","author":"Kehmeier","year":"2012","journal-title":"Clin. Res. Cardiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.tcm.2013.06.003","article-title":"Atherosclerosis and interferon-\u03b3: New insights and therapeutic targets","volume":"24","author":"Voloshyna","year":"2014","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s12013-014-9993-5","article-title":"Treg\/Th17 Ratio Acts as a Novel Indicator for Acute Coronary Syndrome","volume":"70","author":"Li","year":"2014","journal-title":"Cell Biochem. Biophys."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Xia, Y., Gao, D., Wang, X., Liu, B., Shan, X., Sun, Y., and Ma, D. (2024). Role of Treg cell subsets in cardiovascular disease pathogenesis and potential therapeutic targets. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1331609"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/s41467-021-21737-9","article-title":"Cytotoxic CD8+ T cells promote granzyme B-dependent adverse post-ischemic cardiac remodeling","volume":"12","author":"Zlatanova","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000541069","article-title":"Senescent CD4+ T-Cell Phenotypes and Inflammatory Milieu in the Coronary and Systemic Circulation in ST-Elevation Myocardial Infarction: An Exploratory Study","volume":"61","author":"Masso","year":"2024","journal-title":"J. Vasc. Res."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Sch\u00e4fer, S., and Zernecke, A. (2020). CD8+ T Cells in Atherosclerosis. Cells, 10.","DOI":"10.3390\/cells10010037"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1161\/01.CIR.0000096055.62724.C5","article-title":"Inflammatory Cytokines Stimulated C-Reactive Protein Production by Human Coronary Artery Smooth Muscle Cells","volume":"108","author":"Willerson","year":"2003","journal-title":"Circulation"},{"key":"ref_97","first-page":"e93943","article-title":"C-reactive Protein (CRP) Levels as a Predictor of Adverse Cardiovascular Events in Acute Myocardial Infarction: A Prospective Study","volume":"17","author":"Ahtesham","year":"2025","journal-title":"Cureus"},{"key":"ref_98","first-page":"418","article-title":"C-Reactive Protein in Acute Coronary Syndrome. Looking Back in Order to Move Forward","volume":"59","author":"Sanchis","year":"2006","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_99","first-page":"e72","article-title":"Inflammatory Biomarkers in Acute Coronary Syndromes","volume":"113","author":"Armstrong","year":"2006","journal-title":"Circulation"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/1995-705X.96660","article-title":"C-reactive protein as a predictor of adverse outcome in patients with acute coronary syndrome","volume":"13","author":"Sheikh","year":"2012","journal-title":"Heart Views"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jacc.2005.03.077","article-title":"Early and Late Benefits of High-Dose Atorvastatin in Patients with Acute Coronary Syndromes","volume":"46","author":"Ray","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/j.jacc.2009.09.010","article-title":"Effect of Intensive Statin Therapy on Clinical Outcomes Among Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome","volume":"54","author":"Gibson","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Mitsis, A., Sokratous, S., Karmioti, G., Kyriakou, M., Drakomathioulakis, M., Myrianthefs, M.M., Eftychiou, C., Kadoglou, N.P.E., Tzikas, S., and Fragakis, N. (2025). The Role of C-Reactive Protein in Acute Myocardial Infarction: Unmasking Diagnostic, Prognostic, and Therapeutic Insights. J. Clin. Med., 14.","DOI":"10.3390\/jcm14134795"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"EByrne, C., Fitzgerald, A., Cannon, C.P., Fitzgerald, D.J., and Shields, D.C. (2004). Elevated white cell count in acute coronary syndromes: Relationship to variants in inflammatory and thrombotic genes. BMC Med. Genet., 5.","DOI":"10.1186\/1471-2350-5-13"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.amjcard.2007.11.004","article-title":"Usefulness of the Neutrophil to Lymphocyte Ratio in Predicting Long-Term Mortality in ST Segment Elevation Myocardial Infarction","volume":"101","author":"Nunez","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0735-1097(02)02484-1","article-title":"Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes","volume":"40","author":"Sabatine","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.amjcard.2019.12.007","article-title":"Relation of White Blood Cell Count to Bleeding and Ischemic Events in Patients with Acute Coronary Syndrome (from the ATLAS ACS 2-TIMI 51 Trial)","volume":"125","author":"Alkhalfan","year":"2020","journal-title":"Am. J. Cardiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.imr.2018.02.006","article-title":"Neutrophil to lymphocyte ratio as a predictor of myocardial damage and cardiac dysfunction in acute coronary syndrome patients","volume":"7","author":"Chen","year":"2018","journal-title":"Integr. Med. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.47391\/JPMA.S6-ACSA-02","article-title":"The relationship between neutrophil to lymphocyte ratio (NLR) with rehospitalisation and mortality in patients with acute coronary syndrome (ACS)","volume":"74","author":"Lesmana","year":"2024","journal-title":"J. Pak. Med. Assoc."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.repc.2015.01.013","article-title":"Neutrophil-to-lymphocyte ratio predicts coronary artery lesion complexity and mortality after non-ST-segment elevation acute coronary syndrome","volume":"34","author":"Soylu","year":"2015","journal-title":"Rev. Port. Cardiol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/1076029613519850","article-title":"Utility of Neutrophil\u2013Lymphocyte Ratio in Predicting Troponin Elevation in the Emergency Department Setting","volume":"21","author":"Korkmaz","year":"2015","journal-title":"Clin. Appl. Thromb."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","article-title":"Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease","volume":"128","author":"Ridker","year":"2021","journal-title":"Circ. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1002\/jmv.26654","article-title":"Defining IL-6 levels in healthy individuals: A meta-analysis","volume":"93","author":"Said","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e001869","DOI":"10.1136\/openhrt-2021-001869","article-title":"High levels of interleukin-6 are associated with final infarct size and adverse clinical events in patients with STEMI","volume":"8","author":"Shetelig","year":"2021","journal-title":"Open Heart"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ejim.2004.07.013","article-title":"IL-6 levels in acute and post myocardial infarction: Their relation to CRP levels, infarction size, left ventricular systolic function, and heart failure","volume":"15","author":"Gabriel","year":"2004","journal-title":"Eur. J. Intern. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women","volume":"342","author":"Ridker","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Besse, S., Nadaud, S., Balse, E., and Pavoine, C. (2022). Early Protective Role of Inflammation in Cardiac Remodeling and Heart Failure: Focus on TNF\u03b1 and Resident Macrophages. Cells, 11.","DOI":"10.3390\/cells11071249"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Kang, H.-J., Kim, J.-W., Lee, J.-Y., Kim, S.-W., Shin, I.-S., Hong, Y.J., Ahn, Y., Jeong, M.-H., and Kim, J.-M. (2021). Time-Specific Associations of Tumor Necrosis Factor-\u03b1 Levels and Polymorphisms (\u2212850 C\/T or \u2212308 G\/A) with Suicidal Ideation in Acute Coronary Syndrome Patients. Front. Psychiatry, 12.","DOI":"10.3389\/fpsyt.2021.739823"},{"key":"ref_119","first-page":"694","article-title":"TNF-\u03b1 and E-Selectin as Valuable Biomarkers in Patients with Acute Coronary Artery Syndrome","volume":"14","author":"Auda","year":"2025","journal-title":"Int. J. Mol. Cell Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/OAEM.S425319","article-title":"Diagnostic Impact of Hs-CRP and IL-6 for Acute Coronary Syndrome in Patients Admitted to the ED with Chest Pain: Added Value to the HEART Score?","volume":"15","author":"Rafiqi","year":"2023","journal-title":"Open Access Emerg. Med."},{"key":"ref_121","first-page":"25","article-title":"Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: A systematic review of the literature","volume":"37","author":"Madjid","year":"2010","journal-title":"Tex. Heart Inst. J."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"16092","DOI":"10.1038\/s41598-017-16464-5","article-title":"Lipoprotein-associated phospholipase A2 and oxidized low-density lipoprotein in young patients with acute coronary syndrome in China","volume":"7","author":"Huang","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"10760296251360015","DOI":"10.1177\/10760296251360015","article-title":"The Value of Lp-PLA2 as a Biomarker for the Diagnosis of Plaque Stability in Atherosclerosis: A Meta-Analysis","volume":"31","author":"Huang","year":"2025","journal-title":"Clin. Appl. Thromb."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"135625","DOI":"10.1155\/2008\/135625","article-title":"Myeloperoxidase: A New Biomarker of Inflammation in Ischemic Heart Disease and Acute Coronary Syndromes","volume":"2008","author":"Loria","year":"2008","journal-title":"Mediat. Inflamm."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e39891","DOI":"10.1097\/MD.0000000000039891","article-title":"Investigating soluble CD40 ligand as a prognostic factor among acute coronary syndromes patients: A multi-center prospective case-control study","volume":"103","author":"Nofal","year":"2024","journal-title":"Medicine"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Adam, C.A., \u0218alaru, D.L., Prisacariu, C., Marcu, D.T.M., Sasc\u0103u, R.A., and St\u0103tescu, C. (2022). Novel Biomarkers of Atherosclerotic Vascular Disease\u2014Latest Insights in the Research Field. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23094998"},{"key":"ref_127","first-page":"657025","article-title":"Pentraxin 3: A Novel Biomarker for Inflammatory Cardiovascular Disease","volume":"2012","author":"Inoue","year":"2012","journal-title":"Int. J. Vasc. Med."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Ge, P., Ni, T., Liu, M., Du, Q., Xu, C., Hu, T., Gu, Y., Liu, H., and Geng, J. (2025). TRAF3IP2 as a novel inflammatory biomarker for coronary artery disease: Development and validation of a multimodal prediction model. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1644403"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"20228","DOI":"10.1038\/s41598-020-77413-3","article-title":"Identification of plaque ruptures using a novel discriminative model comprising biomarkers in patients with acute coronary syndrome","volume":"10","author":"Kook","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Jin, P., Zhang, S., Yang, L., Zeng, Y., Li, Y., and Tang, R. (2025). Analysis and validation of biomarkers and immune cell infiltration profiles in unstable coronary atherosclerotic plaques using bioinformatics and machine learning. Front. Cardiovasc. Med., 12.","DOI":"10.3389\/fcvm.2025.1451255"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Kumric, M., Borovac, J.A., Martinovic, D., Kurir, T.T., and Bozic, J. (2021). Circulating Biomarkers Reflecting Destabilization Mechanisms of Coronary Artery Plaques: Are We Looking for the Impossible?. Biomolecules, 11.","DOI":"10.3390\/biom11060881"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ebiom.2018.12.033","article-title":"Predictive value of targeted proteomics for coronary plaque morphology in patients with suspected coronary artery disease","volume":"39","author":"Bom","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_133","first-page":"17","article-title":"microRNA-based diagnostics and therapy in cardiovascular disease-Summing up the facts","volume":"5","author":"Schulte","year":"2015","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Wexler, Y., and Nussinovitch, U. (2020). The Diagnostic Value of Mir-133a in ST Elevation and Non-ST Elevation Myocardial Infarction: A Meta-Analysis. Cells, 9.","DOI":"10.3390\/cells9040793"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jacbts.2023.10.007","article-title":"Advances in Clinical Imaging of Vascular Inflammation","volume":"9","author":"West","year":"2023","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e200563","DOI":"10.1148\/ryct.2021200563","article-title":"Assessing Cardiovascular Risk by Using the Fat Attenuation Index in Coronary CT Angiography","volume":"3","author":"Oikonomou","year":"2021","journal-title":"Radiol. Cardiothorac. Imaging"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/ehjci\/jeae313","article-title":"Plasma proteomics improves prediction of coronary plaque progression","volume":"26","author":"Kraaijenhof","year":"2025","journal-title":"Eur. Heart J.-Cardiovasc. Imaging"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00029330-200601010-00006","article-title":"Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome","volume":"119","author":"Feng","year":"2006","journal-title":"Chin. Med. J."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"33","DOI":"10.15420\/ecr.2016:34:2","article-title":"Antiplatelet Therapy in Acute Coronary Syndrome","volume":"12","author":"Layne","year":"2017","journal-title":"Eur. Cardiol. Rev."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1160\/TH15-03-0191","article-title":"Antiinflammatory effects of aspirin in ACS: Relevant to its cardio coronary actions?","volume":"114","author":"Hohlfeld","year":"2015","journal-title":"Thromb. Haemost."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"245037","DOI":"10.1155\/2012\/245037","article-title":"Clinical Use of Aspirin in Treatment and Prevention of Cardiovascular Disease","volume":"2012","author":"Dai","year":"2012","journal-title":"Thrombosis"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejphar.2005.03.012","article-title":"Gentisic acid, an aspirin metabolite, inhibits oxidation of low-density lipoprotein and the formation of cholesterol ester hydroperoxides in human plasma","volume":"513","author":"Ashidate","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/hrt.77.4.333","article-title":"Aspirin protects low density lipoprotein from oxidative modification","volume":"77","author":"Steer","year":"1997","journal-title":"Heart"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.CIR.101.10.1206","article-title":"Aspirin","volume":"101","author":"Awtry","year":"2000","journal-title":"Circulation"},{"key":"ref_145","first-page":"730","article-title":"Aspirin Promotes Low Density Lipoprotein Susceptibility to Oxidative Modification in Healthy Volunteers","volume":"11","author":"Waterman","year":"2009","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/1573403X13666170426104611","article-title":"The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature","volume":"13","author":"Diamantis","year":"2017","journal-title":"Curr. Cardiol. Rev."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.5114\/aoms\/158546","article-title":"The effects of statins on the function and differentiation of blood cells","volume":"19","author":"Chamani","year":"2022","journal-title":"Arch. Med. Sci."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cca.2005.12.040","article-title":"The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome","volume":"368","author":"Zhou","year":"2006","journal-title":"Clin. Chim. Acta"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic Effects of Statins on the Cardiovascular System","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ. Res."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Zivkovic, S., Maric, G., Cvetinovic, N., Lepojevic-Stefanovic, D., and Cvijan, B.B. (2023). Anti-Inflammatory Effects of Lipid-Lowering Drugs and Supplements\u2014A Narrative Review. Nutrients, 15.","DOI":"10.3390\/nu15061517"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e131530","DOI":"10.1172\/jci.insight.131530","article-title":"Effects of rosuvastatin on the immune system in healthy volunteers with normal serum cholesterol","volume":"4","author":"Karmaus","year":"2019","journal-title":"JCI Insight"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4103\/0976-500X.162011","article-title":"Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome","volume":"6","author":"Khurana","year":"2015","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1016\/j.jacc.2009.10.005","article-title":"Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial","volume":"54","author":"Murphy","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40256-022-00546-5","article-title":"Early Statin Therapy and In-Hospital Outcomes in Acute Coronary Syndrome Patients Presenting with Advanced Killip Class at Admission: Findings from the CCC-ACS Project","volume":"22","author":"Song","year":"2022","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/ehjcvp\/pvz022","article-title":"PCSK9 and inflammation: A review of experimental and clinical evidence","volume":"5","author":"Momtazi","year":"2019","journal-title":"Eur. Heart J.-Cardiovasc. Pharmacother."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/heartjnl-2015-307781","article-title":"Cochrane corner: Early statin therapy in acute coronary syndromes\u2014What is the clinical benefit?","volume":"102","author":"Nordmann","year":"2016","journal-title":"Heart"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e023328","DOI":"10.1161\/JAHA.121.023328","article-title":"Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis","volume":"11","author":"Punch","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Katsuki, S., Jha, P.K., Aikawa, E., and Aikawa, M. (2024). The role of proprotein convertase subtilisin\/kexin 9 (PCSK9) in macrophage activation: A focus on its LDL receptor-independent mechanisms. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1431398"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Wu, N.-Q., Shi, H.-W., and Li, J.-J. (2022). Proprotein Convertase Subtilisin\/Kexin Type 9 and Inflammation: An Updated Review. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.763516"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e062046","DOI":"10.1136\/bmjopen-2022-062046","article-title":"PCSK9 inhibitors for anti-inflammation in atherosclerosis: Protocol for a systematic review and meta-analysis of randomised controlled trials","volume":"12","author":"Luo","year":"2022","journal-title":"BMJ Open"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.atherosclerosis.2019.07.015","article-title":"PCSK9 inhibition and inflammation: A narrative review","volume":"288","author":"Ruscica","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e022348","DOI":"10.1136\/bmjopen-2018-022348","article-title":"Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: A systematic review and meta-analysis of randomised controlled trials","volume":"8","author":"Cao","year":"2018","journal-title":"BMJ Open"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.amjcard.2017.02.020","article-title":"Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or with Established Coronary Heart Disease (from the Phase 2 EQUATOR Study)","volume":"119","author":"Baruch","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"117180","DOI":"10.1016\/j.atherosclerosis.2023.06.971","article-title":"Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque","volume":"378","author":"Marfella","year":"2023","journal-title":"Atherosclerosis"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2995602","DOI":"10.1155\/2021\/2995602","article-title":"Ezetimibe Improves Rosuvastatin Effects on Inflammation and Vascular Endothelial Function in Acute Coronary Syndrome Patients Undergoing PCI","volume":"2021","author":"Sun","year":"2021","journal-title":"J. Interv. Cardiol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1253\/circj.CJ-24-0536","article-title":"Addition of Ezetimibe to Intensive Lipid-Lowering Therapy Is Associated with a Lower Incidence of Heart Failure in Patients with Acute Coronary Syndrome","volume":"88","author":"Yoshikawa","year":"2024","journal-title":"Circ. J."},{"key":"ref_170","first-page":"247","article-title":"Ezetimibe: Clinical and Scientific Meaning of the IMPROVE-IT Study","volume":"106","author":"Correia","year":"2016","journal-title":"Arq. Bras. Cardiol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1248\/bpb.b18-00369","article-title":"Role of NLRP3 Inflammasome in Cardiac Inflammation and Remodeling after Myocardial Infarction","volume":"42","author":"Takahashi","year":"2019","journal-title":"Biol. Pharm. Bull."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.2147\/JIR.S383903","article-title":"NLRP3 Inflammasome May Be a Biomarker for Risk Stratification in Patients with Acute Coronary Syndrome","volume":"15","author":"Mo","year":"2022","journal-title":"J. Inflamm. Res."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"4293206","DOI":"10.1155\/2020\/4293206","article-title":"NLRP3 Inflammasome and Its Central Role in the Cardiovascular Diseases","volume":"2020","author":"Tong","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"105575","DOI":"10.1016\/j.intimp.2019.04.022","article-title":"The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction","volume":"74","author":"Gao","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.1038\/s41598-018-24350-x","article-title":"Inhibition of the NLRP3-inflammasome as a potential approach for neuroprotection after stroke","volume":"8","author":"Ismael","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"E1530","DOI":"10.1073\/pnas.1716095115","article-title":"OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation","volume":"115","author":"Marchetti","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/FJC.0000000000000658","article-title":"The NLRP3 Inflammasome Inhibitor, OLT1177 (Dapansutrile), Reduces Infarct Size and Preserves Contractile Function After Ischemia Reperfusion Injury in the Mouse","volume":"73","author":"Toldo","year":"2019","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Fern\u00e1ndez, A., Skouras, D.B., Dinarello, C.A., and L\u00f3pez-Vales, R. (2019). OLT1177 (Dapansutrile), a Selective NLRP3 Inflammasome Inhibitor, Ameliorates Experimental Autoimmune Encephalomyelitis Pathogenesis. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02578"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1161\/ATVBAHA.124.319851","article-title":"Colchicine\u2019s Role in Cardiovascular Disease Management","volume":"44","author":"Buckley","year":"2024","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","article-title":"Colchicine in Patients with Acute Coronary Syn-drome","volume":"142","author":"Tong","year":"2020","journal-title":"Circulation"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11883-021-00932-5","article-title":"Colchicine and Cardiovascular Outcomes: A Critical Appraisal of Recent Studies","volume":"23","author":"Banach","year":"2021","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Ma, Z., Chen, J., Jin, K., and Chen, X. (2022). Colchicine and coronary heart disease risks: A meta-analysis of randomized controlled clinical trials. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.947959"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1161\/CIRCULATIONAHA.121.054610","article-title":"Colchicine in Patients with Acute Coronary Syndrome: Two-Year Follow-Up of the Australian COPS Randomized Clinical Trial","volume":"144","author":"Tong","year":"2021","journal-title":"Circulation"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1093\/eurheartj\/ehaa659","article-title":"Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)","volume":"41","author":"Bouabdallaoui","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa2405922","article-title":"Colchicine in Acute Myocardial Infarction","volume":"392","author":"Jolly","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_188","first-page":"843","article-title":"Efficacy and safety of colchicine and spironolactone after myocardial infarction: The CLEAR-SYNERGY trial in perspective","volume":"13","author":"Tardif","year":"2024","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/ehjcvp\/pvaf011","article-title":"CLEAR results, cloudy impact: Colchicine\u2019s neutral role in ST-segment elevation myocardial infarction","volume":"11","author":"Laudani","year":"2025","journal-title":"Eur. Heart J.-Cardiovasc. Pharmacother."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"695","DOI":"10.21037\/jtd.2018.01.119","article-title":"Anti-inflammatory therapy with canakinumab for atherosclerotic disease: Lessons from the CANTOS trial","volume":"10","author":"Thompson","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1161\/ATVBAHA.117.310097","article-title":"The CANTOS Trial","volume":"37","author":"Baylis","year":"2017","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_192","first-page":"2","article-title":"CANTOS: A breakthrough that proves the inflammatory hypothesis of atherosclerosis","volume":"2018","author":"Hassan","year":"2018","journal-title":"Glob. Cardiol. Sci. Pract."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.amjcard.2013.01.287","article-title":"Effects of Interleukin-1 Blockade with Anakinra on Adverse Cardiac Remodeling and Heart Failure After Acute Myocardial Infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) Pilot Study]","volume":"111","author":"Abbate","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"e062602","DOI":"10.1136\/bmjopen-2022-062602","article-title":"Low-dose interleukin 2 for the reduction of vascular inflammation in acute coronary syndromes (IVORY): Protocol and study rationale for a randomised, double-blind, placebo-controlled, phase II clinical trial","volume":"12","author":"Sriranjan","year":"2022","journal-title":"BMJ Open"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/s44161-025-00658-6","article-title":"Insights from the LILACS trial on translational T cell regulation in cardiology","volume":"4","author":"Ashour","year":"2025","journal-title":"Nat. Cardiovasc. Res."},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Su, J.-H., Luo, M.-Y., Liang, N., Gong, S.-X., Chen, W., Huang, W.-Q., Tian, Y., and Wang, A.-P. (2021). Interleukin-6: A Novel Target for Cardio-Cerebrovascular Diseases. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.745061"},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Dimitroglou, Y., Aggeli, C., Theofilis, P., Tsioufis, P., Oikonomou, E., Chasikidis, C., Tsioufis, K., and Tousoulis, D. (2023). Novel Anti-Inflammatory Therapies in Coronary Artery Disease and Acute Coronary Syndromes. Life, 13.","DOI":"10.3390\/life13081669"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"e933973-1\u2013e933973-3","DOI":"10.12659\/MSM.933973","article-title":"Editorial: Tocilizumab, a Humanized Therapeutic IL-6 Receptor (IL-6R) Monoclonal Antibody, and Future Combination Therapies for Severe COVID-19","volume":"27","author":"Parums","year":"2021","journal-title":"Med. Sci. Monit."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jacc.2021.02.049","article-title":"Randomized Trial of Interleukin-6 Receptor Inhibition in Patients with Acute ST-Segment Elevation Myocardial Infarction","volume":"77","author":"Broch","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s43094-024-00723-0","article-title":"Efficacy and safety of ziltivekimab in patients with chronic kidney disease susceptible to inflammatory diseases: A systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Elrosasy","year":"2024","journal-title":"Future J. Pharm. Sci."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1093\/cvr\/cvab231","article-title":"From RESCUE to ZEUS: Will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?","volume":"117","author":"Ridker","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"S767","DOI":"10.1016\/j.ekir.2024.11.1354","article-title":"WCN25-888 Design of the Zeus Trial: Interleukin 6 Inhibition with Ziltivekimab for Cardiovascular Protection in Chronic Kidney Disease","volume":"10","author":"Perkovic","year":"2025","journal-title":"Kidney Int. Rep."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cardfail.2023.10.024","article-title":"HERMES: Effects Of Ziltivekimab Versus Placebo On Morbidity And Mortality In Patients with Heart Failure with Mildly Reduced Or Preserved Ejection Fraction And Systemic Inflammation","volume":"30","author":"Petrie","year":"2024","journal-title":"J. Card. Fail."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3349\/ymj.2016.57.2.321","article-title":"Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis","volume":"57","author":"Zhang","year":"2016","journal-title":"Yonsei Med. J."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/jama.2014.11061","article-title":"Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome","volume":"312","author":"Braunwald","year":"2014","journal-title":"JAMA"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"17539447231215213","DOI":"10.1177\/17539447231215213","article-title":"Methotrexate and cardiovascular prevention: An appraisal of the current evidence","volume":"17","author":"Mangoni","year":"2023","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/1759720X11436239","article-title":"Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity","volume":"4","author":"Marks","year":"2012","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-Dose Methotrexate for the Prevention of Atherosclerotic Events","volume":"380","author":"Ridker","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1177\/1074248417699884","article-title":"MethotrexaTE THerapy in ST-Segment Elevation MYocardial InfarctionS","volume":"22","author":"Moreira","year":"2017","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/cvr\/cvae057","article-title":"Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: A pilot randomized, double-blind placebo-controlled trial","volume":"120","author":"Farina","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"ref_212","unstructured":"Posey, A., June, C., and Schwab, R. (2025). Chimeric Antigen Receptor T Regulatory Cells for the Treatment of Atherosclerosis. (U.S. patent 12,473,342)."},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Schwab, R.D., Degaramo, D., Hong, S.J., Bi, X., Faruqi, A., Aguilar, W., Brookens, S.K., Keane, J.T., Liu, F., and Musunuru, K. (2025). OxLDL-targeted Chimeric Antigen Receptor T Regulatory Cells Reduce Atherosclerotic Plaque Development. Circulation, 153.","DOI":"10.1161\/CIRCULATIONAHA.125.073987"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"106055","DOI":"10.1016\/j.intimp.2019.106055","article-title":"Inhibition of peptidyl arginine deiminase-4 protects against myocardial infarction induced cardiac dysfunction","volume":"78","author":"Du","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1021\/bi061180d","article-title":"Inhibitors and Inactivators of Protein Arginine Deiminase 4: Functional and Structural Characterization","volume":"45","author":"Luo","year":"2006","journal-title":"Biochemistry"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_217","doi-asserted-by":"crossref","unstructured":"Skrobucha, A., Pindlowski, P., Krajewska, N., Grabowski, M., and Jonik, S. (2024). Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: A comprehensive review. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1446468"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"20420188231222367","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_219","first-page":"100340","article-title":"Anti-inflammatory benefits of semaglutide: State of the art","volume":"36","author":"Yaribeygi","year":"2024","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/dom.14941","article-title":"Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN-6 trial","volume":"25","author":"Kolkailah","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"31824","DOI":"10.1038\/s41598-025-17574-1","article-title":"Effect of GLP-1RA on coronary progression and cardiovascular outcomes in type 2 diabetic patients after PCI: A prospective cohort study","volume":"15","author":"Zeng","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.2174\/0113816128304097240529053538","article-title":"Therapeutic Potential of Sodium-glucose Co-transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists for Patients with Acute Coronary Syndrome: A Review of Clinical Evidence","volume":"30","author":"Karakasis","year":"2024","journal-title":"Curr. Pharm. Des."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1093\/eurheartj\/ehad632","article-title":"What about glucagon-like peptide-1 receptor agonist for all? Recent data and perspectives","volume":"44","author":"Sabouret","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_225","first-page":"2135","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"85","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40119-025-00426-4","article-title":"Beyond Blood Sugar: A Scoping Review of GLP-1 Receptor Agonists in Cardiovascular Care","volume":"14","author":"Gupta","year":"2025","journal-title":"Cardiol. Ther."},{"key":"ref_227","doi-asserted-by":"crossref","unstructured":"Torzewski, J., Brunner, P., Ries, W., Garlichs, C.D., Kayser, S., Heigl, F., and Sheriff, A. (2022). Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons. J. Clin. Med., 11.","DOI":"10.3390\/jcm11071771"},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Torzewski, J., Mattecka, S., Ries, W., Garlichs, C.D., Heigl, F., Fiedler, J., and Sheriff, A. (2023). Case report: C-reactive protein apheresis in cardiogenic shock: Case series from the C-reactive protein apheresis in acute myocardial infarction-registry. Front. Drug Discov., 3.","DOI":"10.3389\/fddsv.2023.1286710"},{"key":"ref_229","doi-asserted-by":"crossref","unstructured":"Ries, W., Torzewski, J., Heigl, F., Pfluecke, C., Kelle, S., Darius, H., Ince, H., Mitzner, S., Nordbeck, P., and Butter, C. (2021). C-Reactive Protein Apheresis as Anti-inflammatory Therapy in Acute Myocardial Infarction: Results of the CAMI-1 Study. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.591714"},{"key":"ref_230","doi-asserted-by":"crossref","unstructured":"Przytu\u0142a, N., Podolec, J., Przew\u0142ocki, T., Podolec, P., and Kab\u0142ak-Ziembicka, A. (2025). Inflammasomes as Potential Therapeutic Targets to Prevent Chronic Active Viral Myocarditis\u2014Translating Basic Science into Clinical Practice. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202509.1796.v1"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.tips.2025.04.007","article-title":"Targeting the NLRP3 inflammasome for inflammatory disease therapy","volume":"46","author":"Cabral","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S2213-8587(23)00316-9","article-title":"Efficacy and safety of bempedoic acid among patients with and without diabetes: Prespecified analysis of the CLEAR Outcomes randomised trial","volume":"12","author":"Ray","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1007\/s11357-023-00794-6","article-title":"Activation of telomerase by TA-65 enhances immunity and reduces inflammation post myocardial infarction","volume":"45","author":"Bawamia","year":"2023","journal-title":"Geroscience"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1093\/eurheartj\/ehaf192","article-title":"2025 ESC Guidelines for the management of myocarditis and pericarditis","volume":"46","author":"Collini","year":"2025","journal-title":"Eur. Heart J."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/1\/72\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:38:07Z","timestamp":1767627487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/1\/72"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":234,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["cells15010072"],"URL":"https:\/\/doi.org\/10.3390\/cells15010072","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]}}}